|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olempska M, Eisenach PA, Ammerpohl O,
Ungefroren H, Fandrich F and Kalthoff H: Detection of tumor stem
cell markers in pancreatic carcinoma cell lines. Hepatobiliary
Pancreat Dis Int. 6:92–97. 2007.PubMed/NCBI
|
|
5
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar
|
|
7
|
Zhou BB, Zhang H, Damelin M, Geles KG,
Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and
opportunities for anticancer drug discovery. Nat Rev Drug Discov.
8:806–823. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Posern G and Treisman R: Actin' together:
Serum response factor, its cofactors and the link to signal
transduction. Trends Cell Biol. 16:588–596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Olson EN and Nordheim A: Linking actin
dynamics and gene transcription to drive cellular motile functions.
Nat Rev Mol Cell Biol. 11:353–365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang DZ, Li S, Hockemeyer D, Sutherland L,
Wang Z, Schratt G, Richardson JA, Nordheim A and Olson EN:
Potentiation of serum response factor activity by a family of
myocardin-related transcription factors. Proc Natl Acad Sci USA.
99:14855–14860. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miralles F, Posern G, Zaromytidou AI and
Treisman R: Actin dynamics control SRF activity by regulation of
its coactivator MAL. Cell. 113:329–342. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pipes GC, Creemers EE and Olson EN: The
myocardin family of transcriptional coactivators: Versatile
regulators of cell growth, migration, and myogenesis. Genes Dev.
20:1545–1556. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goss AM, Tian Y, Cheng L, Yang J, Zhou D,
Cohen ED and Morrisey EE: Wnt2 signaling is necessary and
sufficient to activate the airway smooth muscle program in the lung
by regulating myocardin/Mrtf-B and Fgf10 expression. Dev Biol.
356:541–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li S, Chang S, Qi X, Richardson JA and
Olson EN: Requirement of a myocardin-related transcription factor
for development of mammary myoepithelial cells. Mol Cell Biol.
26:5797–5808. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun Y, Boyd K, Xu W, Ma J, Jackson CW, Fu
A, Shillingford JM, Robinson GW, Hennighausen L, Hitzler JK, et al:
Acute myeloid leukemia-associated Mkl1 (Mrtf-a) is a key regulator
of mammary gland function. Mol Cell Biol. 26:5809–5826. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morita T, Mayanagi T and Sobue K: Dual
roles of myocardin-related transcription factors in epithelial
mesenchymal transition via slug induction and actin remodeling. J
Cell Biol. 179:1027–1042. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu WG, Shang YL, Cong XR, Bian X and Yuan
Z: MicroRNA-135b promotes proliferation, invasion and migration of
osteosarcoma cells by degrading myocardin. Int J Oncol.
45:2024–2032. 2014.PubMed/NCBI
|
|
18
|
Medjkane S, Perez-Sanchez C, Gaggioli C,
Sahai E and Treisman R: Myocardin-related transcription factors and
SRF are required for cytoskeletal dynamics and experimental
metastasis. Nat Cell Biol. 11:257–268. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edwards BK, Brown ML, Wingo PA, Howe HL,
Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, et al:
Annual report to the nation on the status of cancer, 1975–2002,
featuring population-based trends in cancer treatment. J Natl
Cancer Inst. 97:1407–1427. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Perreard L, Fan C, Quackenbush JF, Mullins
M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K,
et al: Classification and risk stratification of invasive breast
carcinomas using a real-time quantitative RT-PCR assay. Breast
Cancer Res. 8:R232006. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X,
Jiang C, Coppola D, Nicosia SV and Cheng JQ: Frequent activation of
AKT2 and induction of apoptosis by inhibition of
phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Oncogene. 19:2324–2330. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maemondo M, Narumi K, Saijo Y, Usui K,
Tahara M, Tazawa R, Hagiwara K, Matsumoto K, Nakamura T and Nukiwa
T: Targeting angiogenesis and HGF function using an adenoviral
vector expressing the HGF antagonist NK4 for cancer therapy. Mol
Ther. 5:177–185. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shimono Y, Zabala M, Cho RW, Lobo N,
Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, et al:
Downregulation of miRNA-200c links breast cancer stem cells with
normal stem cells. Cell. 138:592–603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang H, Rana S, Giese N, Büchler MW and
Zöller M: Tspan8, CD44v6 and alpha6beta4 are biomarkers of
migrating pancreatic cancer-initiating cells. Int J Cancer.
133:416–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B,
Welling TH, Pasca di Magliano M and Simeone DM: c-Met is a marker
of pancreatic cancer stem cells and therapeutic target.
Gastroenterology. 141:2218–2227.e5. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gesierich S, Paret C, Hildebrand D, Weitz
J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn
D, Ashman LK, et al: Colocalization of the tetraspanins, CO-029 and
CD151, with integrins in human pancreatic adenocarcinoma: Impact on
cell motility. Clin Cancer Res. 11:2840–2852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yue S, Mu W and Zöller M: Tspan8 and CD151
promote metastasis by distinct mechanisms. Eur J Cancer.
49:2934–2948. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leitner L, Shaposhnikov D, Mengel A,
Descot A, Julien S, Hoffmann R and Posern G: MAL/MRTF-A controls
migration of non-invasive cells by upregulation of
cytoskeleton-associated proteins. J Cell Sci. 124:4318–4331. 2011.
View Article : Google Scholar
|
|
32
|
Mokalled MH, Johnson A, Kim Y, Oh J and
Olson EN: Myocardin-related transcription factors regulate the
Cdk5/Pctaire1 kinase cascade to control neurite outgrowth, neuronal
migration and brain development. Development. 137:2365–2374. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsuji T, Ibaragi S and Hu GF:
Epithelial-mesenchymal transition and cell cooperativity in
metastasis. Cancer Res. 69:7135–7139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vasioukhin V, Bauer C, Degenstein L, Wise
B and Fuchs E: Hyperproliferation and defects in epithelial
polarity upon conditional ablation of alpha-catenin in skin. Cell.
104:605–617. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schlegelmilch K, Mohseni M, Kirak O,
Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J,
Brummelkamp TR, et al: Yap1 acts downstream of α-catenin to control
epidermal proliferation. Cell. 144:782–795. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Masszi A, Di Ciano C, Sirokmány G, Arthur
WT, Rotstein OD, Wang J, McCulloch CA, Rosivall L, Mucsi I and
Kapus A: Central role for Rho in TGF-beta1-induced alpha-smooth
muscle actin expression during epithelial-mesenchymal transition.
Am J Physiol Renal Physiol. 284:F911–F924. 2003. View Article : Google Scholar
|
|
38
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gavert N and Ben-Ze'ev A:
Epithelial-mesenchymal transition and the invasive potential of
tumors. Trends Mol Med. 14:199–209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sabbah M, Emami S, Redeuilh G, Julien S,
Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O and Gespach C:
Molecular signature and therapeutic perspective of the
epithelial-to-mesenchymal transitions in epithelial cancers. Drug
Resist Updat. 11:123–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang CJ, Chao CH, Xia W, Yang JY, Xiong
Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, et al: p53 regulates
epithelial-mesenchymal transition and stem cell properties through
modulating miRNAs. Nat Cell Biol. 13:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bracken CP, Gregory PA, Kolesnikoff N,
Bert AG, Wang J, Shannon MF and Goodall GJ: A double-negative
feedback loop between ZEB1-SIP1 and the microRNA-200 family
regulates epithelial-mesenchymal transition. Cancer Res.
68:7846–7854. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gregory PA, Bracken CP, Bert AG and
Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal
transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ji Q, Hao X, Zhang M, Tang W, Yang M, Li
L, Xiang D, Desano JT, Bommer GT, Fan D, et al: MicroRNA miR-34
inhibits human pancreatic cancer tumor-initiating cells. PLoS One.
4:e68162009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W,
Liu J, Yu J and Chen J: miRNA-96 suppresses KRAS and functions as a
tumor suppressor gene in pancreatic cancer. Cancer Res.
70:6015–6025. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang F, Xue X, Wei J, An Y, Yao J, Cai H,
Wu J, Dai C, Qian Z, Xu Z, et al: hsa-miR-520h downregulates ABCG2
in pancreatic cancer cells to inhibit migration, invasion, and side
populations. Br J Cancer. 103:567–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li Y, Vandenboom TG II, Wang Z, Kong D,
Ali S, Philip PA and Sarkar FH: miR-146a suppresses invasion of
pancreatic cancer cells. Cancer Res. 70:1486–1495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Greither T, Grochola LF, Udelnow A,
Lautenschläger C, Würl P and Taubert H: Elevated expression of
microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar
|
|
53
|
Dillhoff M, Liu J, Frankel W, Croce C and
Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and
a potential predictor of survival. J Gastrointest Surg.
12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Park JK, Lee EJ, Esau C and Schmittgen TD:
Antisense inhibition of microRNA-21 or -221 arrests cell cycle,
induces apoptosis, and sensitizes the effects of gemcitabine in
pancreatic adenocarcinoma. Pancreas. 38:e190–e199. 2009. View Article : Google Scholar : PubMed/NCBI
|
